drugset / Trial / NCT00833469

Escitalopram (Lexapro) for the Treatment of Postpartum Depression

NCT00833469

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine whether women with postpartum major depressive disorder (MDD) will experience a significant decrease in depressive symptoms from baseline over an eight-week treatment intervention with escitalopram (Lexapro). Also, to determine whether women with postpartum MDD will experience a significant decrease in anxiety symptoms.

Timeline

Start
2009-01
Primary completion
2011-04
Completion
2011-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Escitalopram Small molecule 10 mg Oral

Indications